Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study.
HNSCC
cetuximab
nivolumab
pembrolizumab
real world data
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Mar 2021
09 Mar 2021
Historique:
received:
12
12
2020
revised:
21
02
2021
accepted:
05
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
We hypothesized the combination of cetuximab and nivolumab would improve survival in recurrent and/or metastatic (R/M) HNSCC by providing synergy in cancer control and evaluated toxicities and efficacy of the combination. Effects of sequential administration of cetuximab and anti-Programmed Cell Death-1 checkpoint inhibitors (CPI) were also explored. Patients who failed at least one line of palliative treatment for incurable HNSCC were treated with cetuximab 500 mg/m
Identifiants
pubmed: 33803335
pii: cancers13051180
doi: 10.3390/cancers13051180
pmc: PMC7967147
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : James and Esther King Biomedical Research Grant
ID : 7JK02
Organisme : Lilly Oncology
ID : Not applicable
Organisme : National Cancer Institute, United States
ID : P30-CA076292
Références
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Clin Cancer Res. 2013 Apr 1;19(7):1858-72
pubmed: 23444227
Arch Pathol Lab Med. 2018 May;142(5):559-597
pubmed: 29251996
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
J Clin Oncol. 2014 Dec 10;32(35):3930-8
pubmed: 25267748
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
J Cell Biochem Suppl. 1993;17F:188-91
pubmed: 8412192
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Cancer Sci. 2007 Aug;98(8):1275-80
pubmed: 17498200
J Natl Cancer Inst. 1998 Jun 3;90(11):824-32
pubmed: 9625170
Oral Oncol. 2020 Dec;111:105024
pubmed: 33065374
Clin Investig. 1992 Mar-Apr;70(3-4):320-7
pubmed: 1521046
Psychol Methods. 2010 Sep;15(3):234-49
pubmed: 20822250
J Clin Oncol. 2007 Jun 1;25(16):2171-7
pubmed: 17538161
Mol Cancer Ther. 2019 Nov;18(11):1909-1915
pubmed: 31676542
Lancet Oncol. 2017 Aug;18(8):1104-1115
pubmed: 28651929
N Engl J Med. 2007 May 10;356(19):1944-56
pubmed: 17494927
N Engl J Med. 2007 Oct 25;357(17):1705-15
pubmed: 17960013
J Natl Cancer Inst. 2008 Mar 19;100(6):407-20
pubmed: 18334711
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
J Clin Oncol. 2006 Sep 1;24(25):4170-6
pubmed: 16943533
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Cancer Res. 2015 Jun 1;75(11):2200-10
pubmed: 25832655
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Clin Cancer Res. 2018 Nov 1;24(21):5368-5380
pubmed: 30042205
Clin Cancer Res. 2019 Sep 1;25(17):5221-5230
pubmed: 31239321
Oral Oncol. 2019 Sep;96:7-14
pubmed: 31422216